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Objectives We sought to evaluate the impact of unstable coronary artery disease (CAD) on short- and mid-term outcomes in
patients with multivessel disease treated by multiple sirolimus-eluting stents (SES) as part of ARTS II (Arterial
Revascularization Therapies Study Part II).
Background The differential safety/efficacy profile of SES when implanted in patients with unstable angina (UA) in compari-
son with stable angina (SA) undergoing multivessel intervention is largely unknown.
Methods Between February 2003 and November 2003, 607 patients at 45 participating centers were treated; 221 of
them (36%) presented with UA.
Results At 30 days, the cumulative rate of death, myocardial infarction—defined as any creatine kinase (CK)/CK-
myocardial band elevation beyond the upper limit of normal—cerebrovascular accident, and repeat revascular-
ization (i.e., major adverse cardiac and cerebrovascular events [MACCEs]) was 19.9% in both groups. Angio-
graphic subacute stent occlusion was documented in 1 (0.5%) and 4 (1%) patients in the UA and SA groups,
respectively. At 1 year, the cumulative incidence of MACCEs was 27.1% in the UA and 24.9% in the SA group (p
0.56). Two late occlusions occurred, both in the SA group. After adjustment for baseline and procedural characteris-
tics, the presence of UA was not identified as an independent predictor of MACCE (hazard ratio 0.94; 95% confidence
interval 0.41 to 2.12; p  0.88). These findings remained consistent after increasing the CK/CK-myocardial band
threshold to define periprocedural myocardial infarction up to at least 3 or 5 times the upper limit of normal.
Conclusions In ARTS II, an unstable clinical presentation did not exert a negative impact on short- and mid-term outcome after
SES implantation for multivessel disease. (ARTS II Trial; http://clinicaltrials.gov/ct/show/NCT00235170?order1;
NCT00235170). (J Am Coll Cardiol 2007;49:431–41) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.081(
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hether the net safety/efficacy profile of SES differs in
elation to the acuity (i.e., stable vs. unstable) of clinical
resentation remains an open issue.
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Impact of Clinical Presentation in ARTS II January 30, 2007:431–41The thrombogenic coronary
milieu in patients with an acute
coronary syndrome (ACS), cou-
pled with the well-known pro-
pensity for hypercoagulability in
this patient subset and possible
delayed re-endothelialization
with drug-eluting stents (DES),
has resulted in concerns of an
increased risk of stent thrombosis
after implantation of these de-
vices in patients with ACS (7).
Moreover, several previous stud-
ies have identified unstable an-
gina as a risk factor for restenosis
after BMS implantation (8,9).
ARTS II (Arterial Revascular-
ization Therapies Study Part II)
is a multicenter, European, open-
label, nonrandomized trial evalu-
ating the safety and efficacy of
ES as compared with the previous results of the random-
zed ARTS I trial (10). Thirty-six percent of the 607
atients enrolled in ARTS II had unstable angina at
resentation.
We sought to evaluate whether clinical outcome in this
ubset of patients was comparable with that observed in
atients with stable angina in the attempt to evaluate
hether the net efficacy/safety profile of SES is affected by
cuity of clinical presentation. The 1-year outcome in
RTS II, stratified into stable versus unstable presentation,
lso was compared with that of patients undergoing percu-
aneous or surgical revascularization in ARTS I, in keeping
ith the original design of the study.
ethods
tudy design. The ARTS II study design has been previ-
usly reported (11,12). In brief, patients were consecutively
nrolled via a central telephone service, after stratification by
linical site to ensure the inclusion of at least one-third of
atients undergoing 3-vessel intervention.
election of patients. Patients were eligible for coronary
evascularization if they had either stable angina (Canadian
ardiovascular Society class I, II, III, or IV), unstable
ngina (Braunwald class IB, IC, IIB, IIC, IIIB, or IIIC), or
f they had silent ischemia and at least 2 new lesions located
n different major epicardial vessels and/or their side
ranches (not including the left main coronary artery) that
ere potentially amenable to stent implantation. Patients
ere required to have multivessel disease with the need for
reatment of the left anterior descending artery and at least
ne other significant lesion (50% diameter stenosis) in
nother major epicardial coronary artery. One totally oc-
luded major epicardial vessel also could be included. The
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMS  bare-metal stent
CVA  cerebrovascular
accident
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent
HR  hazard ratio
MACCE  major adverse
cardiac and
cerebrovascular event
MI  myocardial infarction
SES  sirolimus-eluting
stent
TVR  target vessel
revascularizationtenosis had to be amenable to stenting using a stent with a riameter of 2.5 to 3.5 mm and length of 13 to 33 mm,
ithout any restriction on the total stent length implanted.
Patients with any previous coronary intervention, left
ain coronary disease, overt congestive heart failure, or a
eft ventricular ejection fraction of 30% were excluded.
dditional exclusion criteria included a history of a cere-
rovascular accident and ST-segment elevation myocardial
nfarction in the preceding week or with persistent elevation
f creatine kinase (CK).
Patients requiring nonelective treatment, defined as a
rocedure conducted on referral before the beginning of the
ext working day (13), could not be considered for inclu-
ion. Measurement of troponin was not mandatory at
creening. Patients with chest pain lasting longer than 30
in within the preceding 12 h were also excluded if CK was
qual or more than 2 times the upper limit of normal.
Written, informed consent was obtained from each pa-
ient before enrollment. The study was approved by the
thics committee of each participating site.
rocedures and postintervention medications. All inter-
entions were performed according to current standard
uidelines and the final interventional strategy, including
he use of glycoprotein IIb/IIIa inhibitors, was left entirely
o the discretion of the operator, except for the stent
tilization. All patients were advised to maintain lifelong
spirin use. Clopidogrel 300 mg as a loading dose, or
iclopidine, administered at a dose of 500 mg, was to be
tarted at least 24 h before the procedure. Clopidogrel 75
g per day or ticlopidine 250 mg twice a day was prescribed
or at least 2 months after revascularization.
tudy objectives and end points. The primary objective of
his ARTS II subanalysis was to compare the safety and
ffectiveness of coronary stent implantation using SES in
atients with unstable angina with that of patients under-
oing similar treatment for the presence of stable angina.
or the purpose of the present analysis, patients with stable
ngina and silent ischemia (defined as the “stable angina”
roup) were compared with patients who had unstable
ngina, as previously reported in ARTS I (14). The primary
utcome measure was the incidence of major adverse cardiac
nd cerebrovascular events (MACCEs) at 1 year, compris-
ng all-cause death, any cerebrovascular event, nonfatal
yocardial infarction (MI), or any repeat revascularization
either percutaneous or surgical; contemporary comparison).
The secondary objectives of this study are to compare
-year MACCE in the ARTS II patients, stratified accord-
ng to clinical presentation (stable vs. unstable) to that of
atients with stable and unstable angina who randomly were
ssigned to either percutaneous BMS implantation or cor-
nary artery bypass grafting (CABG) in the ARTS I trial
historical comparison).
nd point definitions. All deaths were considered cardiac
nless a noncardiac origin was established clinically or at
utopsy. Death from all causes was reported.
Cerebrovascular events were divided into 3 main catego-
ies: stroke, transient ischemic attack, and reversible isch-
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January 30, 2007:431–41 Impact of Clinical Presentation in ARTS IImic neurologic deficit. In the first 7 days after the inter-
ention, a definite diagnosis of MI was made if there was
ocumentation of new abnormal Q waves (according to the
innesota code) and either a ratio of serum CK-myocardial
and (CK-MB) isoenzyme to total cardiac enzyme that was
0.1 or a CK-MB value that was 5 times the upper limit of
ormal (1,11,12). Serum CK and CK-MB isoenzyme con-
entrations were measured 6, 12, and 18 h after the
ntervention. Beginning 8 days after the intervention (the
ength of the hospital stay after surgery), either abnormal Q
aves or enzymatic changes were sufficient for a diagnosis of
I. This dual method of defining MI was developed for
RTS I to address the difficulty of diagnosing a MI after
ardiac surgery. An MI was confirmed only after the
elevant electrocardiograms had been analyzed by the elec-
rocardiographic core laboratory and adjudicated by an
ndependent clinical events committee. For the purpose of
his analysis, to explore whether the current definition of MI
ay artificially contribute to minimize the impact of clinical
cuity on outcome, the occurrence of non–Q-wave MI in
he first 7 days after the index procedure also has been
eclassified based on any CK or CK-MB elevation or a CK
r CK-MB value that was 3 times or more the upper limit
f normal, in keeping with current American College of
ardiology/American Heart Association and European So-
iety of Cardiology recommendations (15,16). All repeat
evascularization procedures were recorded. Events were
ounted from the time of the initial procedure. Thrombotic
cclusions were defined according to the protocol as either
y angiographic documentation of a complete occlusion
Thrombolysis In Myocardial Infarction [TIMI] flow grade
or 1) or angiographic documentation of a flow-limiting
hrombus (TIMI flow grade 1 or 2).
To allow cross comparisons with other contemporary
nvestigations (17), stent thrombosis also was determined as
he occurrence of any of the following events: angiographic
ocumentation of partial or total stent occlusion detected
ithin 30 days of the procedure (an acute clinical ischemic
vent in addition to angiographic documentation had to be
resent when the event occurred after 30 days) or sudden
ardiac death or postprocedural MI after successful stent
mplantation not clearly attributable to another coronary
esion. All events have been reviewed and adjudicated by an
ndependent clinical events committee.
tatistical analysis. Continuous variables are shown as
ean  SD if not otherwise stated and were compared
sing the Student 2-sample t test. Categorical variables are
resented as percentages and compared with the chi-square
est. Comparison among 3 groups was performed using a
eneral linear model based on a 1-way analysis of variance,
epeated for each of the variables to be explained by
reatment on 3 levels as an explanatory variable. No correc-
ion for multiple analyses was performed because this
rocedure was only used as an entry criterion for the
ultivariable analysis. Survival curves were generated by the
aplan-Meier method, and survival among groups was iompared using the log-rank test. Proportional hazards and
eibull models were used to assess risk reduction of adverse
vents. For the stable versus unstable comparison within the
RTS II study, multivariable analysis, including all vari-
bles mentioned simultaneously in the model and consid-
ring all variables reported in Tables 1 and 2 with a p value
0.10, was performed to adjust for possible confounders
nd to identify whether clinical presentation was an inde-
endent predictor of adverse events. Moreover, a simulta-
eous interaction test of the predicting variables with
linical presentation was performed based on a likelihood
atio test, using the model 2Log Likelihood, stratified by
nginal status and subtracting the sum of the model 2Log
ikelihoods for each analysis by anginal status. This differ-
nce has a chi-square distribution with 2  n  m degrees
f freedom, with n the degrees of freedom in the by anginal
tatus analysis and m being the degrees of freedom in the
tratified analysis. For the comparison of ARTS II versus
RTS I, multivariate analysis considering all variables
eported in Table 3 with a p value 0.1 were considered to
btain the adjusted hazard ratio. Colinearity in the model
as investigated using a correlation matrix and by inspec-
ion of the estimate parameters obtained in the model.
oreover, after standardizing the regressors, the condition
ndex was calculated for each considered variable which
anged from 1 to 3.39, thus excluding the presence of
olinrearity. Probability was significant at a level of 0.05.
ll statistical tests were 2-tailed. Statistical analysis was
erformed with SAS V8.02 (SAS Institute, Cary, North
arolina).
esults
atients. Between February 2003 and November 2003,
07 patients at 45 participating centers were treated. Table
presents their baseline demographic characteristics based
n clinical presentation. The patients were predominantly
ales with preserved left ventricular function; 3-vessel
isease was present in more than 50% of the cases. Patients
ith unstable angina had a slightly lower body mass index
nd were affected less frequently by hypertension and
ypercholesterolemia. The incidence of previous MI in the
nstable group was almost double when compared with the
table patient group. Current smoking was more frequent in
nstable as compared to stable patients. The 2 groups were
therwise comparable for all other baseline characteristics,
ncluding comorbidities.
Overall hospital stay was on average 1.3 days longer in
nstable patients (Table 2). Coronary lesions in patients
ith unstable angina were less frequently calcified and more
requently of type A/B1 than of type B2/C, whereas
hrombus was more commonly observed in this group.
here was no other difference in procedural characteristics
etween the 2 groups, including use of glycoprotein IIb/IIIa
nhibitors (Table 2).
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Impact of Clinical Presentation in ARTS II January 30, 2007:431–41Baseline demographic, procedural characteristics, and
edications at discharge according to clinical presenta-
ion in ARTS II as compared with ARTS I are reported
n Table 3.
RTS II 30-day outcomes. No deaths occurred in the first
aseline Patient Demographics
Table 1 Baseline Patient Demographics
Patient Parameters Measured
Unstable Angina
(n  221 Patients)
Age (yrs)
n 221
Mean  SD 62.6  10.5
(Min–max) (35–80)
Ejection fraction (%)
n 204
Mean  SD 60.0  11.5
(Min–max) (30–97)
Body mass index (kg/m2)
n 220
Mean  SD 27.1  4.2
(Min–max) (15.2–42.9)
Men 74.2% (164/221)
Diabetes mellitus 23.1% (51/221)
Hypertension 62.0% (137/221)
Hypercholesterolemia 65.2% (144/221)
History of CVA 1.4% (3/221)
Family history of MI/SD 55 yrs 35.5% (78/220)
Peripheral vascular disease 7.2% (16/221)
Previous MI 48.0% (106/221)
Previous CABG 0.0% (0/221)
Previous PTCA 0.9% (2/221)
Carotid surgery 1.4% (3/221)
Chronic obstructive pulmonary disease 2.7% (6/221)
Smoking history
Previous 34.8% (77/221)
Current 24.4% (54/221)
Unstable angina 100.0% (221/221)
Braunwald I 23.1% (51/221)
Braunwald Ib 19.9% (44/221)
Braunwald Ic 3.2% (7/221)
Braunwald II 49.3% (109/221)
Braunwald IIb 38.0% (84/221)
Braunwald IIc 11.3% (25/221)
Braunwald III 27.6% (61/221)
Braunwald IIIb 20.8% (46/221)
Braunwald IIIc 6.8% (15/221)
Stable angina —
CCS I —
CCS II —
CCS III —
CCS IV —
Silent ischemia —
Number of diseased arteries —
Single 0.0% (0/221)
Double 47.5% (105/221)
Triple 52.5% (116/221)
raunwald  Braunwald classification; CABG  coronary artery bypass graft; CCS  Canadian
ccident; Difference  unstable angina  stable angina; MI  myocardial infarction; PTCA  per0 days in either group. There were no significant differ- snces in patients with unstable with respect to those with
table angina in the cumulative incidence of MACCE
death, infarction, cerebrovascular accident, or repeat revas-
ularization) during the first 30 days irrespective of the
pplied definition for myocardial infarction (Table 4). The
Stable Angina
 386 Patients) Difference (95% CI) p Value
386
62.9  9.1 0.3 (1.9–1.3) 0.70
(37–80)
334
60.3  11.6 0.3 (2.3–1.7) 0.76
(30–88)
381
27.8  4.0 0.7 (1.4–0.0) 0.036
(18.6–43.0)
8.0% (301/386) 3.8% (10.9%–3.3%) 0.32
8.0% (108/386) 4.9% (12.0%–2.2%) 0.21
0.2% (271/386) 8.2% (16.1%–0.4%) 0.039
8.9% (303/384) 13.7% (21.2%–6.3%) 0.001
0.5% (2/385) 0.8% (0.8%–2.5%) 0.36
6.2% (139/384) 0.7% (8.7%–7.2%) 0.86
6.8% (26/385) 0.5% (3.8%–4.7%) 0.87
6.7% (103/386) 21.3% (13.4%–29.2%) 0.001
0.0% (0/386) 0.0% (0.0%–0.0%)
0.3% (1/386) 0.6% (0.7%–2.0%) 0.30
1.3% (5/385) 0.1% (1.8%–2.0%) 1.00
4.2% (16/385) 1.4% (4.4%–1.5%) 0.50
4.3% (171/386) 9.5% (17.5%–1.5%) 0.026
6.3% (63/386) 8.1% (1.4%–14.9%) 0.018
— — —
— — —
— — —
— — —
— — —
— — —
— — —
— — —
— — —
— — —
3.7% (323/386) — —
1.1% (43/386) — —
2.2% (163/386) — —
7.7% (107/386) — —
2.6% (10/386) — —
6.3% (63/386) — —
0.5% (2/386) 0.5% (1.2%–0.2%) 0.54
5.3% (175/386) 2.2% (6.1%–10.4%) 0.61
4.1% (209/386) 1.7% (9.9%–6.6%) 0.74
ascular Society classification; CI  confidence interval (Diff 1.96·SE); CVA  cerebrovascular
us transluminal coronary angioplasty; SD  sudden death; SE  sqrt(p1·q1/n1  p2·q2/n2).(n
7
2
7
7
3
2
4
1
8
1
4
2
1
4
5ame was true when each component of the MACCE was
s
g
s
a
a
r
v
9
A
i
(
r
v
1
u
H
N , in tota
eter ste
435JACC Vol. 49, No. 4, 2007 Valgimigli et al.
January 30, 2007:431–41 Impact of Clinical Presentation in ARTS IIeparately analyzed (Table 4). Up to discharge, 3 angio-
raphically confirmed thrombotic occlusions occurred in the
table angina group (3 of 386, 0.8%) versus none in unstable
ngina patients (p  0.56). From discharge to 30 days, one
dditional thrombotic occlusion in each group was observed,
esulting in a cumulative rate of 1% in the stable angina
ersus 0.5% in unstable angina group (relative risk [RR] 0.44;
ospital Stay, Procedural Characteristics, and Medications
Table 2 Hospital Stay, Procedural Characteristics, and Medica
Parameters Measured
Unstable Angina
(n  221 Pts,
n  794 Les)
Per-patient analysis
Hospital stay (days)
Mean  SD 6.1  4.6
(Min–max) (1–37)
Days to procedure since enrollment*
Mean  SD 0.1  0.5
(Min–max) (1–4)
Days in hospital since procedure
Mean  SD 3.7  3.1
(Min–max) (1–31)
Duration of procedure (mins)
Mean  SD 86.2  46.3
(Min–max) (10–281)
Number of lesions 50% DS
Mean  SD 3.6  1.3
(Min–max) (2–8)
Number of vessels with a lesion 50% DS
Mean  SD 2.5  0.5
(Min–max) (2–3)
Number of stented lesions
Mean  SD 3.2  1.2
(Min–max) (0–7)
Number of stents implanted
Mean  SD 3.6  1.5
(Min–max) (0–9)
Average stent length (mm)
Mean  SD 19.4  3.5
(Min–max) (13–30)
Total stent length (mm)
Mean  SD 71.3  32.1
(Min–max) (18–209)
IIB/IIIA inhibitors (%) 32.6 (72/221)
Lipid-lowering agent (%) 88.2 (195/221)
Beta-blockers (%) 82.4 (182/221)
Angiotensin-converting enzyme inhibitors (%) 57.9 (128/221)
Per lesion analysis (%)
Ostial lesions 4.7
Moderate-to-heavy calcification 27.4
Thrombus present 1.2
Occlusion 3 months 0.3
Occlusion 3 months 2.3
Lesion classification
Type A/B1 33.0
Type B2/C 67.0
umbers are % (counts/available field sample size) or mean  1 standard deviation. *In ARTS II
CI  confidence interval (Diff1.96·SE); Difference  unstable angina  stable angina; DS  diam5% confidence interval [CI] 0.05 to 3.88; p  0.66). jRTS II 365-day outcomes. At 1 year, the cumulative
ncidence of MACCE was identical in the 2 groups
10.4%, RR 1.00; 95% CI 0.62 to 1.63; p  1.00),
eflecting a similar rate death (0.9% vs. 1.0%), cerebro-
ascular accident (CVA) (0.5% vs. 1.0%), MI (0.9% vs.
.3%), and repeat revascularization (8.1% vs. 7.0%) in
nstable and stable angina groups, respectively. Unad-
Stable Angina
(n  386 Pts,
n  1,365 Les) Difference (95% CI) p Value
4.8  3.9 1.3 (0.6 to 2.0) 0.001
(1–36)
0.1  1.3 0.0 (0.2 to 0.2) 0.92
(7–21)
3.2  2.4 0.5 (0.1 to 1.0) 0.021
(1–30)
84.5  41.4 1.7 (5.5 to 8.9) 0.64
(16–293)
3.5  1.3 0.1 (0.2 to 0.3) 0.62
(1–8)
2.5  0.5 0.0 (0.1 to 0.1) 0.79
(1–3)
3.2  1.1 0.0 (0.2 to 0.2) 0.70
(0–8)
3.7  1.5 0.0 (0.3 to 0.2) 0.72
(0–11)
19.6  3.5 0.3 (0.8 to 0.3) 0.38
(11–31)
73.2  32.1 1.9 (7.2 to 3.4) 0.48
(12–253)
32.4 (125/386) 0.2% (7.5% to 7.9%) 1.00
90.7 (350/386) 2.4% (7.6% to 2.7%) 0.33
74.9 (289/386) 7.5% (0.9% to 14.1%) 0.034
45.6 (176/386) 12.3% (4.1% to 20.5%) 0.004
4.1 0.7% (1.2% to 2.5%) 0.50
33.4 6.0% (10.1% to1.9%) 0.005
0.2 1.0% (0.2% to 1.8%) 0.003
0.1 0.2% (0.2% to 0.6%) 0.56
2.4 0.1% (1.4% to 1.2%) 1.00
28.6 4.5% (0.4% to 8.6%) 0.032
71.4 4.5% (8.6% to0.4%) 0.032
l 6 patients have been enrolled after the procedure.
nosis; Les  lesion; Pts  patients; SD  standard deviation; SE  sqrt(p1·q1/n1  p2·q2/n2).tionsusted Kaplan-Meier estimates of MACCE, death, MI/
CA
C
S
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Impact of Clinical Presentation in ARTS II January 30, 2007:431–41haracteristics: Stable Versus Unstable Angina Group
Table 3 Characteristics: Stable Versus Unstable Angina Group
Unstable Angina Group Stable Angina Group
ARTS II-SES
(n  221 Pts,
n  794 Les)
ARTS I-BMS
(n  226 Pts,
n  628 Les)
ARTS I-CABG
(n  224 Pts,
n  622 Les) p Value
ARTS II-SES
(n  386 Pts,
n  1,366 Les)
ARTS I-BMS
(n  374 Pts,
n  978 Les)
ARTS I-CABG
(n  381) p Value
Male gender (%) 74.2 80.1 75.1 0.27 78 75.1 76.6 0.65
Age, yrs (mean  SD) 62.6  10.5 61  9.6 60.9  9.5 0.12 62.9  9.1 60.5  9.7 61.4  9.2 0.001
BMI, kg/m2 (mean  SD) 27.1  4.2 26.7  3.4 27.1  3.8 0.50 27.8  4 27.5  3.8 27.5  3.6 0.49
Diabetes (%) 23.1 18.6 14.2 0.055 28 18.7 16.8 0.001
Hypertension (%) 62 49.1 43.1 0.001 70.2 42 46.1 0.001
Hypercholesterolemia (%) 65.2 51.3 54 0.007 78.9 61.9 59.7 0.001
Family history (%) 35.5 35.3 42 0.26 36.2 41.5 42 0.20
Current smoking (%) 24.4 32 47.6 0.10 16.3 25.5 21.6 0.008
Previous MI (%) 48 45.1 47.6 0.81 26.7 43.9 38.7 0.001
Stable angina (%) — — — — — — — —
CCS 1 — — — — 11.1 7.8 7.6 0.16
CCS 2 — — — — 42.2 41.7 41.8 0.99
CCS 3 — — — — 27.7 35 37.4 0.01
CCS 4 — — — — 2.6 5.9 5.5 0.05
Silent ischemia (%) — — — — 16.3 9.6 7.6 0.001
Unstable angina (%) — — — — — — — —
Braunwald I 23.1 22.6 19.1 0.54 — — — —
Braunwald Ib 19.9 15.9 16.0 0.47 — — — —
Braunwald Ic 3.2 6.6 3.1 0.14 — — — —
Braunwald II 49.3 50.4 49.8 0.97 — — — —
Braunwald IIb 38 34.1 36.9 0.68 — — — —
Braunwald IIc 11.3 16.4 12.9 0.29 — — — —
Braunwald III 27.6 27 31.1 0.58 — — — —
Braunwald IIIb 20.8 22.6 26.2 0.39 — — — —
Braunwald IIIc 6.8 4.4 4.9 0.53 — — — —
Ejection fraction (%) 60  11.5 62  13.1 58.7  13.6 0.03 60.3  11.6 60.3  11.7 61.3  2.9 0.44
No. of diseased vessels 2.5  0.5 2.3  0.5 2.3  0.6 0.001 2.5  0.5 2.2  0.5 2.3  0.5 0.001
2-vessel (%) 47.5 68.3 61.8 0.001 45.3 68.7 68.8 0.001
3-vessel (%) 52.5 28.9 33.2 0.001 54.1 26.6 28.2 0.001
Location of lesion (%) — — — — — — — —
RCA 31 30.4 28.9 0.70 28.0 31.6 29.8 0.16
LAD 41.1 41.2 41.2 0.99 41.8 38.2 41.0 0.20
CX 28 28.2 29.7 0.74 30.2 30.2 29.1 0.82
No. of lesions treated 3.2  1.2 2.6  1.0 2.9  1.0 0.001 3.2  1.1 2.4  0.9 2.8  1 0.001
Type A/B1 lesions 33 32.2 38.6 0.033 28.6 32.4 37.9 0.001
Type B2/C lesions (%) 67 67.8 61.4 0.033 71.4 67.6 62.1 0.001
No. of stents implanted 3.6  1.5 2.8  1.2 — 0.001 3.7  1.5 2.8  1.3 — 0.001
Total stent length (mm) 71.3  32.1 47.5  19.3 — 0.001 73.2  32.1 47.6  23 — 0.001
Lesion length 10 mm (%) 61.8 67.9 67 0.039 60.3 64.1 68.9 0.001
Lesion length 10–20 mm (%) 26.4 24.4 27.2 0.52 27.7 29.3 24.1 0.029
Lesion length 20 mm (%) 11.7 7.7 5.8 0.001 11.9 6.6 7.0 0.001
Occlusion 3 months (%) 0.3 3.0 4.3 0.001 0.1 3.2 3.9 0.001
Occlusion 3 months (%) 2.3 0.2 1.8 0.001 2.4 0.7 0.8 0.001
Moderate-to-heavy calcification (%) 27.4 16.6 15.4 0.001 33.4 18.1 14.4 0.001
Thrombus present (%) 1.2 1.5 1.7 0.68 0.2 1 1.3 0.001
Maximal dilation pressure (atm) 16.4  2.8 14.9  2.7 — 0.001 16.3  2.9 14.5  2.8 — 0.001
Lipid-lowering agent (%) 88.2 33.0 28.5 0.001 90.7 42.2 33.6 0.001
Beta-blockers (%) 82.4 58.9 57.9 0.001 74.9 60.5 53.0 0.001
ACE inhibitors (%) 57.9 21.9 16.7 0.001 45.6 28.1 14.6 0.001
CE  angiotensin-converting enzyme; ARTS  Arterial Revascularization Therapies Study; BMI  body mass index; BMS  bare-metal stent; CABG  coronary artery bypass grafting; CCS  Canadian
ardiovascular Society classification; CX  left circumflex coronary artery; LAD  left anterior descending artery; Les  lesion; MI  myocardial infarction; Pts  patients; RCA  right coronary artery;
ES  sirolimus-eluting stents.
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January 30, 2007:431–41 Impact of Clinical Presentation in ARTS IIVA, and target vessel revascularization (TVR) are
hown in Figures 1A to 1C, respectively. After reclassi-
ying periprocedural non–Q-wave MI according to cur-
linical Outcome in ARTS II According to Clinical Presentation
Table 4 Clinical Outcome in ARTS II According to Clinical Pres
Unstable Angina
(n  221 Patients
30-day outcome (%)
Nonhierarchical complications
MACCE* 2.7 (6/221)
MACCE† 5.4 (12/221)
MACCE‡ 19.9 (44/221)
Death/CVA/MI* 0.9 (2/221)
Death/CVA/MI† 4.1 (9/221)
Death/CVA/MI‡ 19 (42/221)
Death 0.0 (0/221)
CVA 0.0 (0/221)
Myocardial infarction† 4.1 (9/221)
Q-wave MI 0.9 (2/221)
Non–Q-wave MI* 0.0 (0/221)
Non–Q-wave MI† 3.6 (8/221)
Non–Q-wave MI‡ 18.6 (41/221)
Revascularization 2.3 (5/221)
CABG 1.4 (3/221)
RPTCA 0.9 (2/221)
Subacute occlusion 0.5 (1/221)
Stent thrombosis 0.9 (2/221)
365-day outcome
Hierarchical complications
MACCE* 10.4 (23/221)
MACCE† 12.7 (28/221)
MACCE‡ 27.1 (60/221)
Death 0.9 (2/221)
CVA without death 0.5 (1/221)
MI without death or CVA‡ 19 (42/221)
Q-wave MI 0.9 (2/221)
Non–Q-wave MI* 0.0 (0/221)
Non–Q-wave MI† 2.7 (6/221)
Non–Q-wave MI‡ 19 (42/221)
Revascularization without death or CVA or MI 8.1 (18/221)
CABG without death or CVA or MI 2.3 (5/221)
RPTCA without death or CVA or MI 5.9 (13/221)
Nonhierarchical complications
Death/CVA/MI* 2.3 (5/221)
Death/CVA/MI† 5.0 (11/221)
Death/CVA/MI‡ 20.4 (45/221)
CVA 0.5 (1/221)
Myocardial infarction* 0.9% (2/221)
Myocardial infarction† 4.1 (9/221)
Myocardial infarction‡ 19.5 (43/221)
Revascularization 9.0% (20/221)
CABG 2.7 (6/221)
RPTCA 6.3 (14/221)
Late occlusion 0% (0/221)
Stent thrombosis 0.9% (2/221)
Based on protocol-mandated MI definition. †Based on MI definition of CK/CK-MB 3 times the upp
f normal in one or more sample(s).
ARTS  Arterial Revascularization Therapies Study; CABG  coronary artery bypass grafting;
ACCE  major adverse cardiac and cerebrovascular event; MI  myocardial infarction; RPTCA ent recommendations (15,16), the overall rate of MI at cyear remained similar in patients with stable angina
4.7%) as compared with the group of patients with
nstable angina (4.1%; p  0.84), as was the case for the
ion
Stable Angina
(n  386 Patients)
Relative Risk
(95% CI) p Value
3.4 (13/386) 0.81 (0.31–2.09) 0.81
5.2 (20/386) 1.05 (0.52–2.10) 1.00
19.9 (71/386) 1.00 (0.72–1.39) 1.00
1.0 (4/386) 0.87 (0.16–4.73) 1.00
4.1 (16/386) 0.98 (0.44–2.19) 1.00
19.2 (74/386) 0.99 (0.71–1.39) 1.00
0.0 (0/386) — —
0.3 (1/386) — 1.00
3.9 (15/386) 1.05 (0.47–2.35) 1.00
0.8 (3/386) 1.16 (0.20–6.92) 1.00
0.0 (0/386) — —
3.1 (12/386) 1.16 (0.48–2.8) 0.81
18.1 (70/386) 1.05 (0.72–1.45) 0.91
2.6 (10/386) 0.87 (0.3–2.52) 1.00
1.3 (5/386) 1.05 (0.25–4.34) 1.00
1.3 (4/386) 0.87 (0.16–4.73) 1.00
1 (4/386) 0.70 (0.14–3.57) 1.00
1.5 (6/386) 0.58 (0.12–2.90) 0.77
10.4 (40/386) 1.00 (0.62–1.63) 1.00
11.9 (46/386) 0.80 (0.40–1.60) 0.59
24.9 (96/386) 1.09 (0.83–1.44) 0.56
1.0 (4/386) 0.87 (0.16–4.73) 1.00
1.0 (4/386) 0.44 (0.05–3.88) 0.66
18.9 (73/386) 1.00 (0.72–1.29) 1.00
0.8 (3/386) 1.16 (0.20–6.92) 1.00
0.5 (2/386) — 0.54
3.4 (13/386) 0.82 (0.16–4.73) 0.72
18.7 (72/386) 1.02 (0.72–1.44) 0.91
7.0 (27/386) 1.16 (0.66–2.07) 0.63
1.8 (7/386) 1.25 (0.40–3.88) 0.77
5.2 (20/386) 1.14 (0.58–2.24) 0.71
3.4 (13/386) 0.67 (0.24–1.86) 0.62
6.2 (24/386) 0.80 (0.40–1.60) 0.59
20.7 (80/386) 0.98 (0.71–1.36) 1.00
1 (4/386) 0.44 (0.05–3.88) 0.66
1.6% (6/386) 0.58 (0.12–2.86) 0.72
4.7 (18/386) 0.87 (0.40–1.91) 0.84
19.4 (75/386) 1.00 (0.72–1.40) 1.00
8.0% (31/386) 1.13 (0.66–1.93) 0.65
1.8 (7/386) 1.5 (0.51–4.40) 0.56
6.5 (25/386) 0.98 (0.52–1.84) 1.00
0.5% (2/386) 0.44 (0.05–3.88) 0.54
1.8% (7/386) 0.50 (0.10–2.38) 0.59
of normal in one or more sample(s). ‡Based on MI definition of any CK/CK-MB above upper limit
reatine kinase; CK-MB  creatinine kinase-myocardial band; CVA  cerebrovascular accident;
cutaneous transluminal coronary angioplasty.entat
)
er limitumulative incidence of MACCE based on the revised
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ngina group, p  0.80). Defining non–Q-wave MI as any
K/CK-MB elevation beyond the upper limit of normal
esulted again in a remarkably similar, although unadjusted,
Figure 1 Kaplan-Meier Curves
(A) Major adverse cardiac and cerebrovascular event-free survival; (B) death/
cerebrovascular accident/myocardial infarction-free survival; and (C) freedom
from repeat revascularization in the ARTS II study stratified into unstable
(bold lines) and stable angina (thin lines).utcome in stable as compared with unstable patients in perms of cumulative MI (19.4% vs. 19.5%, p  1.00) or
ACCE (24.9% vs. 27.1%; p  0.56), respectively.
ubgroup and multivariable analysis. Focusing on higher
isk patients presenting with Braunwald class II or III (n 
70), their outcome in terms of MACCE at 30 days (2.4%
s. 3.4%; p  0.72) or 1 year (10% vs. 10.4%; p  0.97) did
ot differ compared with the stable angina group. On the
asis of CK/CK-MB elevation equal to or more than 3
imes the upper limit of normal as a definition of non–Q-
ave MI, the MACCE rate was 4.7% and 12.4% in patients
ith Braunwald class II or III as compared with 5.2% (p 
.99) and 11.9% (p 0.99) in patients with stable angina at
0 and 365 days, respectively. Finally, considering any
K/CK-MB elevation, the MACCE rate was 17.1% vs.
9.9% (p 0.84) at 30 days and 24.7% vs. 24.9% (p 0.94)
t 1 year in patients with class II or III unstable angina
ompared with patients with stable angina.
Using the Weibull modeling and after adjusting for
ovariates as reported in Tables 1 and 2, the clinical status
ailed to become an independent predictor of MACCE
hazard ratio [HR] 0.94, 95% CI 0.41 to 2.12, p  0.88;
R 0.87, 95% CI 0.52 to 1.48, p 0.61; and HR 0.88, 95%
I 0.62 to 1.25; p  0.88 based on periprocedural non–Q-
ave MI definition of CK/CK-MB elevation 5, 3, or
1 times the upper limit of normal, respectively). Similarly,
o statistical interaction was noted between clinical status
nd the tested covariates in the model, irrespective of the
pplied periprocedural MI definition (Fig. 2).
RTS II versus ARTS I. The cumulative incidence of
ACCE, death/MI/CVA, and revascularization at 1 year
tratified according to clinical presentation in the SES group
s compared with the BMS or CABG groups is shown in
igure 3. After adjustment for all confounders among those
eported in Table 3, the MACCE rate observed in the
RTS II study remained consistently lower than that
bserved in the BMS group in stable (HR 0.45, 95% CI
.16 to 0.58, p  0.0004) or unstable patients (HR 0.43,
5% CI 0.18 to 0.99, p  0.034), whereas it did not differ
ompared to the CABG group in stable (HR 2.38, 95% CI
.33 to 16.7, p 0.39) or unstable group (HR 0.33, 95% CI
.03 to 3.22, p  0.34) analyzed separately.
iscussion
espite the growing body of evidence supporting the
enefit of DES in different patients/lesion subsets, informa-
ion regarding their differential safety/efficacy profile in
atients with stable versus unstable angina is scanty and in
art contradictory. Patients undergoing coronary interven-
ion for unstable atherosclerotic coronary lesions are known
o present with a smaller atherosclerotic (18) but larger
hrombotic burden as compared with patients who have
table angina. This justifies the need to evaluate whether
hese devices may perform differently in these 2 patient
ubsets. In the RESEARCH (Randomized Evaluation of
alvage Angioplasty with Combined Utilization of End
oints) registry, where 52% of the population presented
w
f
n
w
(
S
I
v
h
B
o
c
m
r
w
(
t
0
t
439JACC Vol. 49, No. 4, 2007 Valgimigli et al.
January 30, 2007:431–41 Impact of Clinical Presentation in ARTS IIith ACS, patients with and without ACS benefited equally
rom SES implantation, with a relative risk reduction in the
eed for target vessel revascularization at 1 year in both groups
hen compared with BMS of 70% and 61%, respectively (6).
Similar information has been provided by the STRATEGY
Single High-Dose Bolus Tirofiban and Sirolimus-Eluting
tent vs. Abciximab and Bare-Metal Stent in Myocardial
nfarction) trial, in which patients undergoing primary inter-
ention for acute myocardial infarction allocated to receive SES
ad a 70% relative reduction of TVR as compared with the
Figure 2 HRs and 95% CIs of Factors in the Multivariable Mode
There was no observed interaction between the identified outcome predictors in th
definition of myocardial infarction (MI). (A) Results based on non–Q-wave MI defin
limit of normal are shown, with an overall p value of 0.66 for testing interaction. (
tion beyond the upper limit of normal are shown, with an overall p value of 0.58 fo
sin-converting enzyme; CI  confidence interval; DS  diameter stenosis; HR  hMS group (5). In both studies, the rate of thrombotic 0cclusion was low and not different in the SES with respect to
ontrol groups, suggesting that the safety profile of SES is
aintained in patients with ACS.
In a subanalysis of the TAXUS IV trial, an even-lower
estenosis rate was reported in patients with ACS as compared
ith stable patients receiving paclitaxel-eluting stents (PES)
7). However, patients with ACS treated with PES had a trend
oward a higher rate of stent thrombosis at 30 days (0.8% vs.
%, p  0.06) and, of concern, cardiac death at 1 year also
rended higher in patients with ACS receiving PES (2.5% vs.
Anginal Status
el and anginal status at presentation, irrespective of the periprocedural applied
any creatine kinase (CK) or CK-myocardial band elevation 3 times the upper
ults based on non–Q-wave MI defined as any CK or CK-myocardial band eleva-
ing interaction. Blue  stable angina; red  unstable angina. ACE  angioten-
atio; LCX  left circumflex artery.l by
e mod
ed as
B) Res
r test
azard r.7%; p  0.051) (7). Thus, whether there is a specific risk in
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Impact of Clinical Presentation in ARTS II January 30, 2007:431–41atients with ACS undergoing DES implantation remains
argely debatable based on the available data.
In this subanalysis of the ARTS II study, the hypothesis
hat SES may perform differently according to clinical
resentation (i.e., stable vs. unstable), which in itself reflects
difference in biology and coronary plaque composition, has
Figure 3 Kaplan-Meier Curves Out to
1 Year in Both Study Arms
(A) Major adverse cardiac and cerebrovascular event-free survival; (B) death/cere-
brovascular accident/myocardial infarction-free survival; and (C) freedom from
repeat revascularization. Black  sirolimus-eluting stent in the ARTS II study; red
 coronary artery bypass grafting in the ARTS I study; blue  bare-metal stent in
the ARTS I study. Bold lines  unstable angina; thin lines  stable angina.een formally tested. aThe main conclusion of this analysis is that elective
ultivessel patients with unstable angina who are undergo-
ng SES-supported coronary revascularization show a sim-
lar short- and medium-term outcome with respect to those
reated for stable ischemic syndromes. This conclusion is
ased mainly on the similar incidence of major adverse
vents in these 2 groups of patients. It is further reinforced
y the observation that each individual component of
ACCE (i.e., death, reinfarction, CVA, and repeat revas-
ularization) was very similar at 30 days as well as at 1 year
n these 2 groups of patients. The rate of MI and the
umulative rate of MACCE remained remarkably similar at
oth univariate and multivariable-adjusted analysis between
atients with stable and unstable angina after reclassification
f MI based on the elevation of CK/CK-MB at 3 or even 1
imes the upper limit of normal. Focusing on higher-risk
atients, identified according to class II or III of Braunwald
lassification, their short- and long-term outcome was
onsistently similar compared with the stable angina group.
Finally, the rate of thrombotic occlusion, although not
tatistically different between the 2 groups of patients,
ctually was numerically lower in unstable angina patients,
onfirming previous findings (5,6).
These results, based on a contemporary cohort of pa-
ients, were supported by the comparison of outcomes in
RTS II versus ARTS I, stratified according to clinical
resentation. When adjusted for the baseline and procedural
mbalance, the MACCE rate was significantly lower in both
table and unstable patients in the ARTS II with respect to
hose treated with BMS in ARTS I, whereas no difference
as noted with respect to patients allocated to CABG,
rrespective of stable or unstable presentation. The main
nalysis of ARTS II versus ARTS I based on a Bayesian
tatistical approach was reported recently (12). The results
uggested that the use of SES in patients undergoing
ultivessel intervention is equivalent to the rate of major
dverse events as compared with CABG treatment. In the
resent subanalysis, a conventional statistical approach was
sed to separately compare the 2 contemporary patient
ohorts (i.e., unstable angina and stable angina) with the same
istorical cohorts of ARTS I. Our current findings suggest the
fficacy and safety of SES implantation irrespective of stable
ersus unstable presentation in the context of elective multives-
el disease patients undergoing percutaneous intervention.
tudy limitations. Against the consistent background of
avorable results when the treatment with SES is compared
ith BMS implantation in randomized trials so far con-
ucted, the ARTS II study should be regarded as an
ntermediate step before the fulfillment of the next era of
andomized trials of DES-supported percutaneous revascu-
arization versus surgery, such as CARDIA (Coronary
rtery Risk Development in Young Adults), FREEDOM
Future Revascularization Evaluation in Patients With Di-
betes Mellitus: Optimal Management of Multivessel Dis-
ase) and SYNTAX (SYNergy Between PCI With TAXUS
nd Cardiac Surgery), and COMBAT (Comparison of
B
S
A
w
i
T
u
u
p
(
t
d
l
r
B
a
t
f
t
T
o
M
o
n
t
l
t
d
e
o
u
w
t
C
w
a
o
a
a
T
p
d
s
m
r
A
T
t
R
H
m
d
R
1
1
1
1
1
1
1
1
1
441JACC Vol. 49, No. 4, 2007 Valgimigli et al.
January 30, 2007:431–41 Impact of Clinical Presentation in ARTS IIypass Surgery and Angioplasty Using Sirolimus-Eluting
tents in Patients With Unprotected Left Main Coronary
rtery Disease). When ARTS II was designed, the decision
as taken to use a historical control (ARTS I) to assess the
mprovement in clinical outcome when SES are implanted.
his decision precluded the possibility of adjusting for
nmeasured confounders between the 2 groups of individ-
als and necessitates the use of the previous definitions of
rimary end point and patient classification, such as death
cardiac and noncardiac), cerebrovascular accident (e.g.,
ransient ischemic attack, reversible ischemic neurologic
eficit, stroke), MI (Q wave and CK 5 times the upper
imit of normal), all revascularization (without target lesion
evascularization, TVR assessment), ACS (use of original
raunwald classification without systematic troponin tri-
ge), or thrombotic stent occlusion (angiographic defini-
ion). In this study, the antiplatelet regimen was different
rom ARTS I as a result of the mandatory loading dose with
hienopyridines administered 24 h before the intervention.
his may have contributed in part to the more favorable
utcome of ARTS II in comparison with ARTS I-BMS.
oreover, whether the neutral impact of clinical instability
n outcome observed here is reproducible in the context of
onsystematic thienopyridines pretreatment remains to be
ested. Similarly, our results reasonably apply to medium- to
ow-risk ACS patients and cannot be extrapolated to pa-
ients with ongoing or recent myocardial necrosis, haemo-
ynamic instability, or refractory ischemia because they were
xcluded from the study. Finally, despite the rate of confirmed
r possible stent thrombosis was numerically even lower in the
nstable angina group both at 30 days and 1 year compared
ith the stable angina group, we cannot rule out the possibility
hat a type II error may have confounded our findings.
onclusions. In elective patients with multivessel disease
ho underwent SES-supported coronary revascularization
fter adequate pretreatment with thienopyridines, the rate
f short- and medium-term major adverse events was not
ffected by acuity of clinical presentation, irrespective of the
pplied definition of periprocedural myocardial infarction.
he performance of SES in patients with multivessel disease
resenting with both stable and unstable coronary syn-
romes appears a promising alternative to conventional
urgical revascularization. This hypothesis, however, re-
ains to be formally tested in the setting of a prospective
andomized controlled trial.
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